by | Oct 8, 2024 | Lupus Foundation of America
Each year, Medicare beneficiaries are given the opportunity to select a new plan for the upcoming year during the Open Enrollment Period. This year, Open Enrollment begins on October 15 and will run until December 7, 2024.New this year: Medicare Part D prescription...
by | Oct 7, 2024 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Kezar Life Sciences’ zetomipzomib, an investigational therapy for lupus nephritis (LN). This comes after Kezar Life Sciences reported they had voluntarily ended enrollment and dosage of their...
by | Oct 1, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers examined children with childhood-onset systemic lupus erythematosus (cSLE) and the association between race and social determinants of health (SDOH) on the individual or neighborhood-level with achievement of modified low lupus disease...
by | Sep 26, 2024 | Lupus Foundation of America, News & Events
Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody designed to attack CD20, a protein found on certain types of B cells...
by | Sep 25, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers looked to identify unique biomarkers and shared microbial mechanisms among different autoimmune diseases and found that the gut microbiome plays a critical role. Systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD, a...
by | Sep 24, 2024 | Lupus Foundation of America, News & Events
UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE). The primary outcome measure of the study was improvement of...
